The Positives & Negatives of Follistatin Gene Therapy & Telomere Lengthening
A short Optispan discussion of a company's follistatin gene therapy claims, covering the evidence behind them, the telomere debate and a comparison with supplements.
With Optispan host (not named in the captions), Optispan guest (not named in the captions)
Key moments
Tap a moment to play the video from there.
- 0:00Skepticism about epigenetic age graphThe guest looks at a company's graph claiming large epigenetic age reductions and says an epigenetic test is one metric, not biological age. He says he does not trust sellers presenting their own results.
- 0:39Is longer telomere length good?The host asks whether lengthening telomeres is good or bad. The guest says people argue both sides and cites an association between short immune-cell telomeres and higher all-cause mortality.
- 0:55Guest's view on telomeres and cancerThe guest says he links telomere extension in other tissues to cancer mechanisms and describes shortening as a safeguard that cancers can escape. He reads longer telomeres as a possible sign of something good or bad.
- 1:47The single follistatin longevity paperThe guest says only one paper reports lifespan extension from follistatin gene therapy in preclinical studies, which also combined it with telomerase gene therapy. He asks what the actual evidence is.
- 2:36Criticisms of the paperThe guest lists the small preclinical study of about eight subjects, the comparison with more than 100 per intervention in the Interventions Testing Program, a duplicated figure and two corrections including undisclosed financial ties.
- 4:07Why the 30% figure may misleadThe guest says the control group was short-lived. He estimates the effect at about 12 to 13% against a typical lifespan of about 900 days, versus roughly 1,000 days in treated subjects.
- 5:08Human data and risk versus rewardThe guest says the human study he knows of is correlative and ties follistatin expression to poor pulmonary function. He says he sees little evidence yet for the reward side.
- 5:40Muscle mass versus longevity claimsThe guest says increased muscle mass is probably real since it is a known follistatin effect, but the longevity piece lacks data.
- 6:10Supplements versus gene therapyThe guest says he has argued against starting a supplement on one study, but calls a gene therapy obtained abroad a different matter from a supplement made under good manufacturing processes.
What the video says
This is a short clip from Optispan in which a host and a guest react to a graph from a company promoting follistatin gene therapy. The captions do not name either speaker. The wider conversation is about longevity claims, and this clip covers the follistatin portion.
The guest starts with the graph, which claims large reductions in epigenetic age and some telomere lengthening in clients. He says an epigenetic test is one metric of age-related changes, not biological age, and that he does not trust a source that is selling something. On telomeres, the guest says people argue both sides. He says shorter telomeres in the immune system are associated with higher all-cause mortality. He also says that lengthening telomeres in other tissues is something he links to cancer, since cells use shortening as a safeguard and cancers can escape it by extending their telomeres. He sees longer telomeres as possibly a sign of something good or something bad.
The guest then turns to the evidence for follistatin gene therapy as a longevity intervention. He says that, to his knowledge, there is one paper, based on preclinical studies, and that it has been widely criticized. He raises the small preclinical study of about eight subjects, a duplicated figure that led to a correction, and a second correction for undisclosed financial ties to a gene therapy company. He stresses that this does not mean the paper is wrong. He also argues that the headline lifespan gain of about 30% looks closer to 12 to 13% when compared against typical lifespans, because the control group was short-lived.
Finally, the guest says the only human data he knows of is correlative and links follistatin expression to poor pulmonary function. He thinks the muscle mass gains are probably real, but sees little evidence yet for a longevity benefit. The two close by contrasting supplements sold on a single study with a gene therapy obtained abroad, which the guest calls a different matter.
On each compound
Follistatin-3441:47
The speakers discuss follistatin gene therapy, not the peptide itself. The guest says the only longevity evidence is one preclinical paper with significant flaws, and that increased muscle mass is probably real while a longevity benefit is unproven.
See how your DNA reads Follistatin-344“science should not be done on YouTube.”
“I'm just saying nobody's reproduced it yet.”
What this video doesn’t settle
- The guest's figures, such as the 12 to 13% estimate and lifespans of 900 and 1,000 days, are given from memory, and he says he would need to check the paper.
- The video does not show the company's graph in detail or establish whether its epigenetic age and telomere results are accurate.
- The guest's view that telomere extension relates to cancer is his own summary, and the video does not present evidence for it.
Questions this video answers
What evidence is there that follistatin gene therapy extends lifespan?
The guest says there is a single paper reporting lifespan extension in preclinical studies, and that nobody has reproduced it yet. He says it has been criticized for a very small preclinical study of about eight subjects, a duplicated figure and undisclosed conflicts of interest.
Why does the guest question the 30% lifespan extension claim?
He says the control group was short-lived, so the percentage looks inflated. He estimates the effect at about 12 to 13% if controls had lived the roughly 900 days he says is typical, against about 1,000 days for treated subjects.
Does the guest think lengthening telomeres is good or bad?
He says people argue both sides and does not give a firm answer. He mentions an association between short immune-cell telomeres and higher all-cause mortality, and also says that extending telomeres in other tissues is something he links to cancer.
What does the guest say about follistatin and muscle mass?
He says increased muscle mass is one of the things follistatin is known to do and that he is sure that effect is real. He adds that the longevity side is probably lacking in data.
How does the guest compare gene therapy with supplements?
He says he has gone on record against starting a supplement based on one study. He still calls gene therapy obtained abroad a different matter, since a supplement, if the law is followed, will be made under good manufacturing processes.
Video by Optispan on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
